Great Britain
Spikevax JN.1▼ (mRNA - 1273.167) dispersion for injection
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Spikevax JN.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with official recommendations.
Spikevax XBB.1.5▼ 0.1 mg/mL (andusomeran) dispersion for injection
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
Northern Ireland
Spikevax JN.1▼ (mRNA - 1273.167) dispersion for injection
Spikevax JN.1 will be supplied to Northern Ireland under the provisions of NIMAR (Northern Ireland MHRA Authorised Route).
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Spikevax JN.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months and older. The use of this vaccine should be in accordance with official recommendations.
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report a side effect at any time by visiting by visiting the UK's MHRA Yellow Card Reporting Site or by visiting Moderna's Adverse Event Intake Portal.
By reporting side effects you can help provide more information on the safety of this medicine.
Contact Moderna
How can we help you?
Report a Side Effect:
UK's MHRA Yellow Card Site or Moderna's Adverse Event Intake Portal
Email Us: WeCare@modernatx.com
Call Us: 0800 085 7562 Monday - Friday 09:00 to 17:00 GMT (closed holidays)
Moderna Biotech Distributor UK Ltd. Registered in England and Wales No. 14200885
Registered Office: 54 Portland Place, London W1B 1DY